Skip to main content
OpenTrials
Completed

NCT Number: NCT06336135

Reduction in Symptoms After Laser Therapy With Acorn aHFS

This study evaluates the severity and duration of symptoms experienced after laser therapy comparing four post-procedure topical products. Each product is applied to an individual region of interest (5 cm diameter) on the back or décolleté according to randomization code after laser therapy. The subject, blind to the product applied to each of 4 regions of interest, assesses eight symptoms daily for 14 days. Photography is performed daily.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Aging

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Rejuuv Medi Spa

Markham, Ontario, L3R0M3, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female
  • Age: ≥18 and ≤60 years
  • Any skin tone Fitzpatrick score 1-2 (light), 3-4 (medium), 5-6 (dark)
  • Competent and willing to provide written, informed consent to participate in all study activities

Exclusion criteria

  • Pregnant women
  • Are participating/have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by Sponsor
  • Use of retinoids 7 days prior to the procedure
  • Active cutaneous infections in the treatment area
  • Diseases that could inhibit healing, such as scleroderma, or other cutaneous conditions that could confound study results
  • Subjects unable to communicate with the investigator and staff
  • Any health condition that in the investigator's opinion should preclude participation in this study

Treatment and study plan

autologous hair follicle derived secretome

Other

aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.

Other names: Acorn autologous hair follicle secretome, aHFS

Primary outcomes

  1. Reduction in severity and duration of symptoms

    Time frame: 2 weeks

    Each region of interest will be evaluated daily for the severity and duration of eight symptoms

Sponsors and collaborators

Lead sponsor

Acorn Biolabs Inc.

Industry

Registry information

Official study title

A Prospective, Single-blind, Randomized, Placebo-controlled, Clinical Trial Evaluating Reduction in Severity and Duration of Symptoms After Laser Therapy With Acorn aHFS

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 28, 2024
Registry last updated
Dec 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.